Neuroendocrine tumors. Biotherapy

U Plöckinger; B Wiedenmann

doi:10.1016/j.beem.2007.01.002

Neuroendocrine tumors. Biotherapy

Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):145-62. doi: 10.1016/j.beem.2007.01.002.

Authors

U Plöckinger¹, B Wiedenmann

Affiliation

¹ Interdisziplinäres Stoffwechsel-Centrum, Med. Klinik m. S. Hepatologie und Gastroenterologie, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, 13353 Berlin, Germany. ursula.ploeckinger@charite.de

PMID: 17382270
DOI: 10.1016/j.beem.2007.01.002

Abstract

This review gives an introduction to the classification and staging of neuroendocrine tumors, as the prognostic implications of these classifications influence therapeutic decisions. The indications for biotherapy are given, together with a short update on the mechanism of somatostatin analogs and interferon-alpha therapy. This is followed by an in-depth description of the use of biotherapy, its results with respect to symptomatic and antiproliferative treatment, as well as its side-effects.

Publication types

Review

MeSH terms

Acromegaly / therapy
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Biological Therapy* / adverse effects
Dose-Response Relationship, Drug
Humans
Interferons / administration & dosage
Interferons / adverse effects
Interferons / therapeutic use
Neuroendocrine Tumors / therapy*
Somatostatin / administration & dosage
Somatostatin / analogs & derivatives
Somatostatin / therapeutic use

Substances

Antineoplastic Agents
Somatostatin
Interferons